ing an additional unintended pregnancy with ulipristal acetate as compared to levonorgestrel is estimated to be 418€ . Ulipristal acetate is most cost-effective in the subgroup of intake within 24 hours, where it is more efficacious at a lower cost compared to levonorgestrel. ConClusions: Ulipristal acetate is a cost-effective alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy with ulipristal acetate is less than the average cost of said pregnancies. Therefore, French minors should have free access to ulipristal acetate directly in a pharmacy. Ulipristal acetate should be used rapidly after unprotected intercourse (within 24hours) to benefit from its cost-saving potential compared to levonorgestrel use.
peanut 5 (21%), egg 3 (13%), fish 1 (4%) and fruits 1 (4%). Peanut could be reintroduced to all children after CRD, egg and milk after specific IgE IVD. Prior to the introduction of food a secondary care specialist food provocation was performed to confirm the IVD result. ConClusions: CRD ISAC was beneficial in 54% of the cases and in 21% of the cases it was critical for decision making. The aim of the study was reached as avoidance diets decreased by 63%. The results indicate, even with low patient recruitment, it is likely that introducing ISAC IVD to traditional diagnostic algorithm can be considered cost-effective, with an average cost per avoided unnecessary diet for 480 EURs per child. To confirm the findings a larger study will be executed.
were extracted alongside whether the priority status, pre-or post-NOC pCODR submission, and if the drug was a first submission or line extension. Statistical comparisons were made using Student's t-test. RESULTS: 32 pCODR reports were extracted with an average of 203 days between pCODR submission to recommendation, with a wide variation between different drugs (range: 119-329 days, median: 198). There was no significant variation in the average time required for pCODR decision-making based on priority status (prioritisation granted: 232 days, [n= 3]; prioritisation not granted: 202 days, [n= 29]; p= 0.17). There was also no significant variation in time required for line extensions versus first submissions (line extension: 197 days, [n= 9]; first submissions: 205 days, [n= 23]; p= 0.34). pCODR decision-making time did also not significantly vary between those submitted prior-versus post-regulatory approval (pre-NOC: 213 days, [n= 18]; post-NOC: 191 days, [n= 14]; p= 0.26). CONCLUSIONS: Although there are some wide variations in the time required for pCODR to issue recommendations between different drugs, this did not correlate with prioritisation status, whether the drug was a first submission or line extension, or if a submission was made pre-or post-NOC in a statistically significant manner. However, the small sample sizes may have precluded finding statistical significances. Further research is needed to define the key factors underlying this variation. PCN157 ImPaCt of federal regulatIoN oN aCCess to oral ChemotheraPy (oC) aNd hormoNal theraPy (ht) IN
Objectives: To estimate long-term clinical outcomes of using rilpivirine/tenofovir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 copies/ml in the Russian Federation. MethOds: The mathematical model was developed in Microsoft Office 2013. The time horizon was 5 years. The model included two submodels: Markov's model and tree-decision model. The following outcome measures were used in present study: Number of deaths, Years of life lost, Number of hospitalizations. All calculations were based on results of published clinical, epidemiological and social researches. Data for patients with HIV was obtained from prior epidemiological studies that had been provided in the Russian Federation. Results: The number of deaths on rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) was 12% and 15% less, the number of YLL was 9% and 12% less and Number of hospitalizations was 19,91% and 19,88% less than on the schemes efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Results obtained with present model showed that treatment naïve patients with HIV-1 RNA< 100 000 copies/ml using rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) can be associated with better long-term outcomes compared to alternative multi-pill schemes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.